Search
MDs To Be /
BY: Alessandro Cau, BSc (Hons)
November 2022
Background Four million people currently live with chronic kidney disease in Canada, ... cotransporter-2 inhibitor (SGLT2i), in patients with type 2 diabetes, empagliflozin use was unexpectedly found to ... factors such as patient comorbidities and side effect profiles as well as which SGLT2i have documented renal and ...